We thank Dr McCarron et al for their concise review of cardiac magnetic resonance (CMR) and its role in pulmonary hypertension (PH). It is important for any multidisciplinary team caring for patients with PH to be aware of the information provided by other imaging modalities not discussed in our article. These modalities include echocardiography and CMR in the diagnosis, prognosis, and functional evaluation of PH. 1 Whereas the role of echocardiography has been clearly established on a large scale, CMR is not yet as consistently used. Many small randomized controlled trials and observational trials have proven the effectiveness of CMR in evaluating treatment, 2 but more work is needed to understand its clinical relevance and to incorporate it into routine use. The quality of advanced imaging modalities can be variable, and it is suggested that centers of excellence for MRI may be necessary to improve cost effectiveness and diagnostic yield. 3 Our article was intended more to encourage the general pulmonologist and radiologist reading chest roentgenograms and CT scans to be cognizant of signs that may suggest the presence of disease, to allow for earlier recognition of PH. 4 Patients with World Health Organization Functional Class (WHO-FC) I or II PH, who lack evidence of right ventricular (RV) dysfunction, have a 1-year mortality of < 5% in contrast to those considered high risk (WHO-FC III or IV with severe RV dysfunction) with a 1-year mortality of > 10%. 1 Given this increase in mortality with progression of disease, the focus must be on early diagnosis and treatment. There is clearly an unacceptable delay in the diagnosis of PH: in one Australian study, there was an overall average delay of 3.9 years from symptom onset to right heart catheterization, which was associated with a significant decline in functional status during that time period. 5 Our hope is to avoid late diagnosis of PH by understanding its presence as indicated by chest radiography, although there are more definitive tests to assess the prognosis and severity of PH. As the role of CMR becomes better defined, it is clear it will become an integral part of PH evaluation and follow-up, but this was out of the scope of our article.
Broad Spectrum Vasopressors Support Sparing Strategies in Vasodilatory Shock Beyond the Vascular Receptors
To the Editor:
Squara et al 1 in their article (August 2019) stated that "everything should be made as simple as possible, but not simpler." The combination of three concepts could be useful in achieving better results against the high rates of mortality in critically ill patients. These three concepts are as follows: (1) use of "broad-spectrum vasopressors" 2 ; (2) vasopressor-sparing strategies 3, 4 ; and (3) microcirculation protection. 5 "Broad-spectrum vasopressors": Considering that patients have a variable response to catecholamines and non-catecholamine agents, as well as the fact that response to different vasopressor classes is neither uniform nor predictable, this approach suggests that the shock treatment must be started with multiple chestjournal.org vasopressors with a different mechanism of action. The vasopressor sensitivity is assessed and "de-escalated" accordingly. Although norepinephrine is used worldwide as a first-line vasopressor, most of the time it is routinely associated with catecholamines targeting the same adrenergic receptors. A more logical association would be with a non-catecholamine vasopressor (eg, vasopressin, angiotensin II). In other words, there is no sense of a norepinephrine association with epinephrine. It should be emphasized that this view considers only receptor-dependent effects. 1 "Catecholamine vasopressor support-sparing strategies": These strategies have the same purpose in protecting the microcirculation. Fluids and amines are critical in keeping cardiovascular pressures sufficient for organ perfusion; as time goes by, however, microcirculatory damages inevitably occur. It is therefore necessary to pursue adjunctive therapeutic options to reduce vasoactive support requirements without compromising arterial pressure. 2, 3 "Microcirculatory protection": This concept is the oldest. It assumes that even with arterial pressure under control with increasing amine concentrations, microvasculature failure is unavoidable. Therefore, special attention focused individually on microcirculation is needed. 4 We guess that a combination of these three concepts will be useful in achieving better results against the high rates of mortality in critically ill patients. Some remarks should be mentioned based on these concepts.
1. High doses of "broad-spectrum vasopressors" have been considered a suitable strategy to treat vasoplegic circulatory shock. However, these vasopressors high doses cause progressive and, many times, irreversible microcirculation injury that should be counteracted adopting "vasopressor support sparing strategies." 2. These protocols do not have to be considered as "rescue" therapy; indeed, it is essential that a precocious "window of opportunity" be used. 3. The search should be continued for novel vasopressor agents, such as synthetic human angiotensin II, which would increase blood pressure and reduce the need for high doses of catecholamine vasopressors. 4. Optimistically, if possible, new vasopressors should be sought that increase the arterial blood pressure without microcirculatory damage.
Cardiogenic shock may be associated with an inflammatory reaction. This possibility has motivated us experimentally and clinically in the use of methylene blue in the last 25 years. 6 The main target of vasopressors are membrane receptors. Therefore, would it not be more more logical to associate them with drugs that interfere with messengers beyond membranes?
